Chronic Myeloid Leukemia (CML) Treatment Market Report 2026

The chronic myeloid leukemia (cml) treatment market size has grown strongly in recent years. It will grow from $8.64 billion in 2025 to $9.23 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to improved diagnostic accuracy for hematological cancers, wider availability of first-generation tkis, increased awareness of cml, expansion of oncology treatment centers, improved patient survival rates.

The chronic myeloid leukemia (cml) treatment market size is expected to see strong growth in the next few years. It will grow to $12.17 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing development of novel targeted agents, rising adoption of combination therapies, expansion of precision oncology programs, growing focus on treatment adherence, increasing investments in oncology research. Major trends in the forecast period include increasing adoption of targeted therapy regimens, rising use of next-generation tkis, growing focus on molecular diagnostics, expansion of personalized treatment protocols, enhanced emphasis on long-term disease management.

The increasing incidence and prevalence of chronic myeloid leukemia (CML) are expected to drive the growth of the chronic myeloid leukemia (CML) treatment market in the coming years. Chronic myeloid leukemia, also referred to as chronic myelogenous leukemia, is a type of cancer that affects the blood and bone marrow and is characterized by the excessive production of immature white blood cells known as myeloid cells. Treatment for chronic myeloid leukemia (CML) helps slow disease progression and prevents advancement to more severe stages. For example, in March 2023, according to the American Society of Clinical Oncology, a US-based professional organization representing physicians across oncology subspecialties, approximately 35,730 individuals in the United States (19,860 men and 15,870 women) were expected to be diagnosed with multiple myeloma in 2023, with an estimated 12,590 deaths (7,000 men and 5,590 women). Therefore, the rising incidence and prevalence of the chronic myeloid leukemia (CML) population are contributing to the growth of the chronic myeloid leukemia (CML) treatment market.

Major companies operating in the chronic myeloid leukemia (CML) treatment market are increasingly focusing on strategic partnerships and collaborations to broaden their product portfolios, speed up commercialization efforts, and expand their geographic presence. These partnerships allow biotechnology companies to benefit from specialized expertise in areas such as regulatory support, market access, and oncology commercialization, enabling faster delivery of innovative therapies to patients. For instance, in February 2023, Xspray Pharma, a Sweden-based biotechnology company, entered into a partnership with EVERSANA, a US-based life sciences commercialization firm, to support the US launch and commercialization of Dasynoc (XS004) for the treatment of chronic myeloid leukemia (CML) and acute lymphatic leukemia (ALL). Dasynoc, a differentiated therapeutic option pending FDA approval and legal requirements, is expected to enter the $3.5 billion US tyrosine kinase inhibitor market. Through this collaboration, Xspray Pharma gains access to EVERSANA’s oncology-focused commercialization team, supporting a tailored and efficient market entry strategy. Planned for launch in the second half of 2023, Dasynoc is expected to enhance treatment options for patients with CML and ALL in the United States.

In January 2025, Handa Therapeutics, a US-based pharmaceutical company, acquired the FDA-approved chronic myeloid leukemia (CML) drug PHYRAGO (dasatinib) tablets for an undisclosed sum. This acquisition is intended to strengthen Handa Therapeutics’ oncology portfolio, improve access to targeted CML treatments, support revenue growth through an established regulatory-approved product, and reinforce its position in the hematologic malignancies market. Nanocopoeia, LLC is a US-based research company.

Major companies operating in the chronic myeloid leukemia (cml) treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Incyte Corporation, Cipla Limited, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, Lupin Limited, Innovent Biologics Inc., Glenmark Pharmaceuticals Limited, Il-Yang Pharmaceutical Co. Ltd., Accord Healthcare Inc., ARIAD Pharmaceuticals Inc., Orca Bio, Bio-Path Holdings Inc.

North America was the largest region in the chronic myeloid leukemia (CML) treatment market in 2025. The regions covered in the chronic myeloid leukemia (cml) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic myeloid leukemia (cml) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the chronic myeloid leukemia treatment market by increasing costs of imported active pharmaceutical ingredients, specialty drug formulations, laboratory reagents, and advanced diagnostic tools. Treatment providers in North America and Europe are most affected due to dependence on cross-border pharmaceutical supply chains, while Asia-Pacific faces pricing pressure on drug manufacturing and exports. These tariffs are contributing to higher therapy costs and reimbursement challenges. At the same time, they are encouraging localized drug production, regional API manufacturing, and domestic investments in oncology drug development.

The chronic myeloid leukemia (cml) treatment market research report is one of a series of new reports that provides chronic myeloid leukemia (cml) treatment market statistics, including chronic myeloid leukemia (cml) treatment industry global market size, regional shares, competitors with a chronic myeloid leukemia (cml) treatment market share, detailed chronic myeloid leukemia (cml) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the chronic myeloid leukemia (cml) treatment industry. This chronic myeloid leukemia (cml) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chronic myeloid leukemia (CML) treatment involves the management of chronic myeloid leukemia, a cancer that affects the blood and bone marrow. Chronic myeloid leukemia is marked by the uncontrolled proliferation of abnormal white blood cells known as myeloid cells. These cells normally play a role in fighting infections and supporting the body’s immune system.

The primary types of chronic myeloid leukemia (CML) treatment include targeted therapy, chemotherapy, radiation therapy, splenectomy, and stem cell transplantation. Targeted therapy is a form of cancer treatment in which drugs are designed to specifically target the genes and proteins that promote the growth and survival of cancer cells. In chronic myeloid leukemia (CML) treatment, targeted therapy is used to identify and eliminate specific cancer cell types while minimizing damage to healthy cells. The drugs used include tyrosine kinase inhibitors, antimetabolites, and others, and they are administered in hospitals, clinics, and other healthcare settings. Medications related to chronic myeloid leukemia (CML) treatment are available through hospital pharmacies, retail pharmacies, and online pharmacies.

The chronic myeloid leukemia (CML) treatment market includes revenues earned by entities by providing targeted therapy with tyrosine kinase inhibitors (TKIs). The chronic myeloid leukemia market includes Imatinib, Dasatinib, Nilotinib, Bosutinib, Ponatinib, and Asciminib. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.